SEC Form 4 · accession 0001567619-19-005515
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqueline Studer
Officer — CVP, Gen. Counsel & Secretary
Period of report
Feb 25, 2019
Accepted (ET)
Feb 27, 2019 · 5:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 25, 2019 | M | 1,156 | $79.54 | A | 6,918 | D | |
| Common StockF1 | Feb 25, 2019 | S | 1,223 | $211.6985 | D | 5,695 | D | |
| Common Stock | Feb 25, 2019 | S | 472 | $212.0522 | D | 5,223 | D | |
| Common StockF2 | Feb 26, 2019 | S | 834 | $208.0617 | D | 4,389 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right-to-buy)F4,F3 | $79.54 | Feb 25, 2019 | M | 1,156 | D | — | Feb 13, 2025 | Common Stock | 1,156 | 708 | D |
Explanation of responses
- F1Represents the weighted average sales price of the shares sold ranging from a low of $211.00 to a high of $211.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F2Represents the weighted average sales price of the shares sold ranging from a low of $208.00 to a high of $208.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F3Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F4Not applicable.